Rapid Micro Biosystems (NASDAQ:RPID – Get Rating) is one of 43 publicly-traded companies in the “Analytical instruments” industry, but how does it weigh in compared to its peers? We will compare Rapid Micro Biosystems to similar companies based on the strength of its institutional ownership, risk, valuation, earnings, dividends, analyst recommendations and profitability.
Earnings & Valuation
This table compares Rapid Micro Biosystems and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Rapid Micro Biosystems||$23.23 million||-$73.52 million||-0.21|
|Rapid Micro Biosystems Competitors||$1.16 billion||$344.59 million||-27.17|
This table compares Rapid Micro Biosystems and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Rapid Micro Biosystems||-296.26%||-44.23%||-25.78%|
|Rapid Micro Biosystems Competitors||-250.85%||6.38%||-11.11%|
Institutional and Insider Ownership
69.8% of Rapid Micro Biosystems shares are owned by institutional investors. Comparatively, 61.5% of shares of all “Analytical instruments” companies are owned by institutional investors. 38.0% of Rapid Micro Biosystems shares are owned by company insiders. Comparatively, 13.3% of shares of all “Analytical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a breakdown of recent ratings for Rapid Micro Biosystems and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Rapid Micro Biosystems||0||1||3||0||2.75|
|Rapid Micro Biosystems Competitors||329||1347||1834||59||2.45|
Rapid Micro Biosystems presently has a consensus price target of $22.67, indicating a potential upside of 413.98%. As a group, “Analytical instruments” companies have a potential upside of 29.54%. Given Rapid Micro Biosystems’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Rapid Micro Biosystems is more favorable than its peers.
About Rapid Micro Biosystems (Get Rating)
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Rapid Micro Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapid Micro Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.